Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 2 Diabetes
Status:
Recruiting
Trial end date:
2024-10-31
Target enrollment:
Participant gender:
Summary
This is a 26-week randomized, open-label, multicenter, active-controlled parallel group
trial. The purpose of this study is to compare efficacy and safety of THDB0206 injection with
insulin lispro injection combined with insulin glargine injection U-100 in Chinese
participants with T2DM.